Goldman Sachs Downgrades Altimmune to Neutral, Lowers Price Target to $6
Goldman Sachs analyst Corinne Jenkins downgrades Altimmune (NASDAQ:ALT) from Buy to Neutral and lowers the price target from $20 to $6.
StoneX Taps AirCarbon Pte. Ltd To Form US Digital Carbon Marketplace
StoneX Group Inc. ("StoneX") and AirCarbon Pte. Ltd. ("ACX") have signed an agreement to create a digital carbon marketplace in the United States as part of the StoneX platform. The new
Argus Research Maintains Buy on FedEx, Raises Price Target to $240
Argus Research analyst John Eade maintains FedEx (NYSE:FDX) with a Buy and raises the price target from $200 to $240.
JMP Securities Reiterates Market Outperform on W.P. Carey, Maintains $86 Price Target
JMP Securities analyst Mitchell Germain reiterates W.P. Carey (NYSE:WPC) with a Market Outperform and maintains $86 price target.
Stephens & Co. Reiterates Overweight on Akoya Biosciences, Maintains $16 Price Target
Stephens & Co. analyst Mason Carrico reiterates Akoya Biosciences (NASDAQ:AKYA) with a Overweight and maintains $16 price target.
Wells Fargo Maintains Underweight on Molina Healthcare, Lowers Price Target to $282
Wells Fargo analyst Stephen Baxter maintains Molina Healthcare (NYSE:MOH) with a Underweight and lowers the price target from $307 to $282.
Needham Maintains Buy on Stagwell, Lowers Price Target to $8
Needham analyst Laura Martin maintains Stagwell (NASDAQ:STGW) with a Buy and lowers the price target from $9 to $8.
Ellomay Capital Marks US Solar Photovoltaic Market Foray
Ellomay Capital Ltd. (NYSE:ELLO) (TASE: ELLO) ("Ellomay" or the "Company"), a renewable energy and power generator and developer of renewable energy and power projects
Deutsche Bank Maintains Buy on Colgate-Palmolive, Lowers Price Target to $80
Deutsche Bank analyst Steve Powers maintains Colgate-Palmolive (NYSE:CL) with a Buy and lowers the price target from $84 to $80.
Fermium Research Downgrades Univar Solns to Hold, Raises Price Target to $36.15
Fermium Research analyst Frank Mitsch downgrades Univar Solns (NYSE:UNVR) from Buy to Hold and raises the price target from $35 to $36.15.